Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy

Claudia Brandt, Patricia Seja, Kathrin Töllner, Kerstin Römermann, Philip Hampel, Markus Kalesse, Andi Kipper, Peter W. Feit, Kasper Lykke, Trine Lisberg Toft-Bertelsen, Pauliina Paavilainen, Inkeri Spoljaric, Martin Puskarjov, Nanna MacAulay, Kai Kaila, Wolfgang Löscher

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Alkuperäiskielienglanti
LehtiNeuropharmacology
Vuosikerta143
Sivut186-204
Sivumäärä19
ISSN0028-3908
DOI - pysyväislinkit
TilaJulkaistu - joulukuuta 2018
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3112 Neurotieteet
  • 1184 Genetiikka, kehitysbiologia, fysiologia

Lainaa tätä

Brandt, Claudia ; Seja, Patricia ; Töllner, Kathrin ; Römermann, Kerstin ; Hampel, Philip ; Kalesse, Markus ; Kipper, Andi ; Feit, Peter W. ; Lykke, Kasper ; Toft-Bertelsen, Trine Lisberg ; Paavilainen, Pauliina ; Spoljaric, Inkeri ; Puskarjov, Martin ; MacAulay, Nanna ; Kaila, Kai ; Löscher, Wolfgang. / Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy. Julkaisussa: Neuropharmacology. 2018 ; Vuosikerta 143. Sivut 186-204.
@article{65942d271569433dbd84382c34862e1a,
title = "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy",
keywords = "Epilepsy, Anti-seizure drugs, Neonatal seizures, GABA, Giant depolarizing potentials, CATION-CHLORIDE COTRANSPORTERS, GIANT DEPOLARIZING POTENTIALS, WATER PERMEABILITY, PILOCARPINE MODEL, ANIMAL-MODELS, PYRAMIDAL NEURONS, DRUG DISCOVERY, KINDLED RATS, GABA ACTIONS, AQUAPORIN 4, 3112 Neurosciences, 1184 Genetics, developmental biology, physiology",
author = "Claudia Brandt and Patricia Seja and Kathrin T{\"o}llner and Kerstin R{\"o}mermann and Philip Hampel and Markus Kalesse and Andi Kipper and Feit, {Peter W.} and Kasper Lykke and Toft-Bertelsen, {Trine Lisberg} and Pauliina Paavilainen and Inkeri Spoljaric and Martin Puskarjov and Nanna MacAulay and Kai Kaila and Wolfgang L{\"o}scher",
note = "Correction Volume: 143 Pages: 349-350 DOI: 10.1016/j.neuropharm.2018.10.012",
year = "2018",
month = "12",
doi = "10.1016/j.neuropharm.2018.09.025",
language = "English",
volume = "143",
pages = "186--204",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Scientific Publ. Co",

}

Brandt, C, Seja, P, Töllner, K, Römermann, K, Hampel, P, Kalesse, M, Kipper, A, Feit, PW, Lykke, K, Toft-Bertelsen, TL, Paavilainen, P, Spoljaric, I, Puskarjov, M, MacAulay, N, Kaila, K & Löscher, W 2018, 'Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy', Neuropharmacology, Vuosikerta 143, Sivut 186-204. https://doi.org/10.1016/j.neuropharm.2018.09.025

Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy. / Brandt, Claudia; Seja, Patricia; Töllner, Kathrin; Römermann, Kerstin; Hampel, Philip; Kalesse, Markus; Kipper, Andi; Feit, Peter W.; Lykke, Kasper; Toft-Bertelsen, Trine Lisberg; Paavilainen, Pauliina; Spoljaric, Inkeri; Puskarjov, Martin; MacAulay, Nanna; Kaila, Kai; Löscher, Wolfgang.

julkaisussa: Neuropharmacology, Vuosikerta 143, 12.2018, s. 186-204.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy

AU - Brandt, Claudia

AU - Seja, Patricia

AU - Töllner, Kathrin

AU - Römermann, Kerstin

AU - Hampel, Philip

AU - Kalesse, Markus

AU - Kipper, Andi

AU - Feit, Peter W.

AU - Lykke, Kasper

AU - Toft-Bertelsen, Trine Lisberg

AU - Paavilainen, Pauliina

AU - Spoljaric, Inkeri

AU - Puskarjov, Martin

AU - MacAulay, Nanna

AU - Kaila, Kai

AU - Löscher, Wolfgang

N1 - Correction Volume: 143 Pages: 349-350 DOI: 10.1016/j.neuropharm.2018.10.012

PY - 2018/12

Y1 - 2018/12

KW - Epilepsy

KW - Anti-seizure drugs

KW - Neonatal seizures

KW - GABA

KW - Giant depolarizing potentials

KW - CATION-CHLORIDE COTRANSPORTERS

KW - GIANT DEPOLARIZING POTENTIALS

KW - WATER PERMEABILITY

KW - PILOCARPINE MODEL

KW - ANIMAL-MODELS

KW - PYRAMIDAL NEURONS

KW - DRUG DISCOVERY

KW - KINDLED RATS

KW - GABA ACTIONS

KW - AQUAPORIN 4

KW - 3112 Neurosciences

KW - 1184 Genetics, developmental biology, physiology

U2 - 10.1016/j.neuropharm.2018.09.025

DO - 10.1016/j.neuropharm.2018.09.025

M3 - Article

VL - 143

SP - 186

EP - 204

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -